Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review)

International Journal of Oncology

Volumn 40, Issue 3, 2012, Pages 639-644

  Hafsi, Sameh ^a   Pezzino, Franca Maria ^a   Candido, Saverio ^a   Ligresti, Giovanni ^a,e   Spandidos, Demetrios A ^b   Soua, Zohra ^c   McCubrey, James A ^d   Travali, Salvatore ^a   Libra, Massimo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF CRETE   (Greece)

^c UNIVERSITY OF SOUSSE   (Tunisia)

^d EAST CAROLINA UNIVERSITY   (United States)

^e VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

AKT; Cancer; Gene mutations; PI3k pathway; PIK3CA

Indexed keywords

ANTHRACYCLINE; GROWTH FACTOR; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TUMOR SUPPRESSOR PROTEIN;

CANCER CHEMOTHERAPY; CELL CYCLE; CELL GROWTH; CELL INVASION; CELL METABOLISM; CELL SURVIVAL; CELL TRANSFORMATION; DRUG RESISTANCE; ENZYME ACTIVITY; GENE DELETION; GENE MUTATION; GENETIC CODE; HUMAN; METASTASIS; MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

ANIMALS; DRUG RESISTANCE; GENETIC VARIATION; HUMANS; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION;

EID: 84857184141     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1312     Document Type: Review

References (40)

1. Kumar A and Carrera AC: New functions for PI3K in the control of cell division. Cell Cycle 6: 1696-1698, 2007. (Pubitemid 47327920)
2. Bader AG, Kang S and Vogt PK: Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 103: 1475-1479, 2006. (Pubitemid 43191190)
3. Corvera S and Czech MP: Direct targets of phosphoinositide 3-kinase products in membrane traffic and signal transduction. Trends Cell Biol 8: 442-446, 1998. (Pubitemid 28529717)
4. Brazil DP, Park J and Hemmings BA: PKB binding proteins. Getting in on the Akt. Cell 111: 293-303, 2002. (Pubitemid 35341386)
5. Yoeli-Lerner M and Toker A: Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell Cycle 5: 603-605, 2006.
6. Vazquez F and Devreotes P: Regulation of PTEN function as a PIP3 gatekeeper through membrane interaction. Cell Cycle 5: 1523-1527, 2006. (Pubitemid 44091972)
7. Simpson L and Parsons R: PTEN: life as a tumor suppressor. Exp Cell Res 264: 29-41, 2001. (Pubitemid 32989079)
8. Leslie NR and Downes CP: PTEN function: how normal cells control it and tumour cells lose it. Biochem J 382: 1-11, 2004. (Pubitemid 39141560)
9. Weinberg RA: How cancer arises. Sci Am 275: 62-70, 1996.
10. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, et al: High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554, 2004. (Pubitemid 38541907)
11. Huang CH, Mandelker D, Schmidt-Kittler O, Samuels Y, Velculescu VE, Kinzler KW, Vogelstein B, Gabelli SB and Amzel LM: The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 318: 1744-1748, 2007. (Pubitemid 350274378)
12. Kang S, Bader AG and Vogt PK: Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 102: 802-807, 2005. (Pubitemid 40282746)
13. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, et al: Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7: 561-573, 2005. (Pubitemid 40799249)
14. Ali IU, Schriml LM and Dean M: Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 91: 1922-1932, 1999.
15. Engelman JA, Luo J and Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606-619, 2006. (Pubitemid 44100518)
16. Chow LM and Baker SJ: PTEN function in normal and neoplastic growth. Cancer Lett 241: 184-196, 2006. (Pubitemid 44163047)
17. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, Wigler MH, Downes CP and Tonks NK: The lipid phosphatase activity of PTEN is critical for its tumor suppressor function. Proc Natl Acad Sci USA 95: 13513-13518, 1998. (Pubitemid 28523003)
18. Steelman LS, Bertrand FE and McCubrey JA: The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. Expert Opin Ther Targets 8: 537-550, 2004. (Pubitemid 40028365)
19. Zbuk KM and Eng C: Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer 7: 35-45, 2007. (Pubitemid 46020845)
20. Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI and Boyd J: Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res 57: 3657-3659, 1997. (Pubitemid 27381202)
21. Singh B, Ittmann MM and Krolewski JJ: Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus. Genes Chromosomes Cancer 21: 166-171, 1998. (Pubitemid 28081244)
22. Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H, Pavletich NP, Carver BS, Cordon-Cardo C, Erdjument-Bromage H, et al: Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 128: 141-156, 2007. (Pubitemid 46048885)
23. Gupta A, Yang Q, Pandita RK, Hunt CR, Xiang T, Misri S, Zeng S, Pagan J, Jeffery J, Puc J, et al: Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle 8: 2198-2210, 2009.
24. Datta SR, Brunet A and Greenberg ME: Cellular survival: A play in three Akts. Genes Dev 13: 2905-2927, 1999.
25. Staal SP, Huebner K, Croce CM, Parsa NZ and Testa JR: The AKT1 proto-oncogene maps to human chromosome 14, band q32. Genomics 2: 96-98, 1988.
26. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN and Testa JR: AKT2, a putative oncogene encoding a member of a subfamily of proteinserine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 89: 9267-9271, 1992.
27. Nakatani K, Thompson DA, Barthel A, Sakaue H, Liu W, Weigel RJ and Roth RA: Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer cell lines. J Biol Chem 274: 21528-21532, 1999.
28. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, et al: A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448: 439-444, 2007. (Pubitemid 47123510)
29. Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, et al: Molecular alterations of the Akt oncogene in ovarian and breast carcinomas. Int J Cancer 64: 280-285, 1995.
30. Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, Lazar AJ, Gershenwald JE and Mills GB: A novel Akt3 mutation in melanoma tumours and cell lines. Br J Cancer 99: 1265-1268, 2008.
31. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, et al: Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158, 2007. (Pubitemid 46398669)
32. Jin W, Wu L, Liang K, Liu B, Lu Y and Fan Z: Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells. Br J Cancer 89: 185-91, 2003. (Pubitemid 36897956)
33. Page C, Lin HJ, Jin Y, Castle VP, Nunez G, Huang M and Lin J: Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res 20: 407-416, 2000. (Pubitemid 30189787)
34. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J and Fan Z: HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22: 3205-3212, 2003. (Pubitemid 36712932)
35. Liedtke C, Cardone L, Tordai A, Yan K, Gomez HL, Figureoa LJ, Hubbard RE, Valero V, Souchon EA, Symmans WF, et al: PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer. Breast Cancer Res 10: 27, 2008.
36. Hudis CA: Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357: 39-51, 2007.
37. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726, 2002. (Pubitemid 34111379)
38. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, et al: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395-402, 2007. (Pubitemid 47539306)
39. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, et al: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127, 2004. (Pubitemid 39485684)
40. Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, et al: PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68: 1953-1961, 2008. (Pubitemid 351416582)